|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRK5 |
Gene summary for GRK5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRK5 | Gene ID | 2869 |
| Gene name | G protein-coupled receptor kinase 5 | |
| Gene Alias | FP2025 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P34947 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2869 | GRK5 | C21 | Human | Oral cavity | OSCC | 3.83e-02 | 4.94e-02 | 0.2678 |
| 2869 | GRK5 | C30 | Human | Oral cavity | OSCC | 1.13e-04 | 1.87e-01 | 0.3055 |
| 2869 | GRK5 | EOLP-1 | Human | Oral cavity | EOLP | 6.96e-12 | 5.71e-01 | -0.0202 |
| 2869 | GRK5 | EOLP-2 | Human | Oral cavity | EOLP | 8.73e-06 | 4.40e-01 | -0.0203 |
| 2869 | GRK5 | NEOLP-1 | Human | Oral cavity | NEOLP | 9.59e-13 | 6.62e-01 | -0.0194 |
| 2869 | GRK5 | NEOLP-2 | Human | Oral cavity | NEOLP | 6.35e-05 | 3.32e-01 | -0.0196 |
| 2869 | GRK5 | NEOLP-3 | Human | Oral cavity | NEOLP | 4.85e-05 | 3.71e-01 | -0.0191 |
| 2869 | GRK5 | SYSMH1 | Human | Oral cavity | OSCC | 1.10e-02 | -8.22e-02 | 0.1127 |
| 2869 | GRK5 | SYSMH4 | Human | Oral cavity | OSCC | 3.92e-02 | -1.31e-01 | 0.1226 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| GO:00467779 | Oral cavity | OSCC | protein autophosphorylation | 123/7305 | 227/18723 | 2.31e-06 | 2.93e-05 | 123 |
| GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
| GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
| GO:004677713 | Oral cavity | EOLP | protein autophosphorylation | 49/2218 | 227/18723 | 2.04e-05 | 3.21e-04 | 49 |
| GO:001605532 | Oral cavity | NEOLP | Wnt signaling pathway | 93/2005 | 444/18723 | 1.35e-10 | 1.34e-08 | 93 |
| GO:019873832 | Oral cavity | NEOLP | cell-cell signaling by wnt | 93/2005 | 446/18723 | 1.73e-10 | 1.66e-08 | 93 |
| GO:004677722 | Oral cavity | NEOLP | protein autophosphorylation | 45/2005 | 227/18723 | 3.28e-05 | 4.87e-04 | 45 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414442 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
| hsa040622 | Oral cavity | EOLP | Chemokine signaling pathway | 42/1218 | 192/8465 | 3.02e-03 | 9.66e-03 | 5.70e-03 | 42 |
| hsa0414452 | Oral cavity | EOLP | Endocytosis | 71/1218 | 251/8465 | 5.28e-09 | 8.97e-08 | 5.29e-08 | 71 |
| hsa0406211 | Oral cavity | EOLP | Chemokine signaling pathway | 42/1218 | 192/8465 | 3.02e-03 | 9.66e-03 | 5.70e-03 | 42 |
| hsa0414461 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
| hsa0414471 | Oral cavity | NEOLP | Endocytosis | 62/1112 | 251/8465 | 3.56e-07 | 4.92e-06 | 3.09e-06 | 62 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRK5 | SNV | Missense_Mutation | novel | c.715N>A | p.Glu239Lys | p.E239K | P34947 | protein_coding | deleterious(0) | benign(0.046) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRK5 | SNV | Missense_Mutation | novel | c.226G>C | p.Gly76Arg | p.G76R | P34947 | protein_coding | tolerated(0.15) | benign(0.226) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| GRK5 | SNV | Missense_Mutation | novel | c.1656G>C | p.Gln552His | p.Q552H | P34947 | protein_coding | tolerated(0.62) | benign(0) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| GRK5 | SNV | Missense_Mutation | novel | c.214N>A | p.Glu72Lys | p.E72K | P34947 | protein_coding | tolerated(0.11) | benign(0.324) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| GRK5 | SNV | Missense_Mutation | c.913N>C | p.Glu305Gln | p.E305Q | P34947 | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GRK5 | SNV | Missense_Mutation | rs368432841 | c.850G>A | p.Glu284Lys | p.E284K | P34947 | protein_coding | tolerated(0.06) | benign(0.184) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| GRK5 | SNV | Missense_Mutation | rs770147450 | c.859N>T | p.Arg287Trp | p.R287W | P34947 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| GRK5 | SNV | Missense_Mutation | rs556570876 | c.1669C>T | p.Arg557Trp | p.R557W | P34947 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
| GRK5 | SNV | Missense_Mutation | novel | c.679N>T | p.Gly227Trp | p.G227W | P34947 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRK5 | SNV | Missense_Mutation | rs771181138 | c.1628N>T | p.Pro543Leu | p.P543L | P34947 | protein_coding | tolerated(0.11) | benign(0.399) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | JNJ-7706621 | JNJ-7706621 | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | ALISERTIB | ALISERTIB | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | citalopram | CITALOPRAM | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | Beta Blocking Agents | 18425130,21127457 | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | BDBM50173330 | |||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | DNDI1417467 | CHEMBL1997335 | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | MLN-8054 | MLN-8054 | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | escitalopram | ESCITALOPRAM | ||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | BDBM50173323 | |||
| 2869 | GRK5 | G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | Antihypertensives | 18425130,21127457 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |